11:05 AM EDT, 07/01/2024 (MT Newswires) -- Valneva SE ( VALN ) said Monday it has received the European Commission authorization to market its single-dose vaccine, IXCHIQ, for the prevention of disease caused by the chikungunya virus in adults aged 18 and above.

The decision was supported by data from a pivotal phase 3 study, demonstrating a 98.9% seroresponse rate 28 days after a single vaccination, the company said.

Valneva said it expects to deliver the first doses of IXCHIQ in Europe by Q4.

Price: 7.19, Change: -0.16, Percent Change: -2.18